M. Dickerson

发表

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021.

William F. Fadel, S. E. Reese, C. Mcevoy, 2021, MMWR. Morbidity and mortality weekly report.

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, medRxiv.

Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers.

Andrew L. Phillips, Thomas P. Fabrizio, Lauren E. W. Olsho, 2022, JAMA.

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Lauren E. W. Olsho, A. Fowlkes, K. Ellingson, 2021, The New England journal of medicine.

Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States

William F. Fadel, M. Stockwell, R. Link-Gelles, 2022, JAMA network open.

Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

William F. Fadel, S. E. Reese, M. Stockwell, 2022, MMWR. Morbidity and mortality weekly report.

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022

William F. Fadel, C. Mcevoy, M. Stockwell, 2022, MMWR. Morbidity and mortality weekly report.

Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines

Andrew L. Phillips, Lauren E. W. Olsho, K. Hegmann, 2021, medRxiv.

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2022, MMWR. Morbidity and mortality weekly report.

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021

William F. Fadel, Sarah E. Reese, C. Mcevoy, 2021, MMWR. Morbidity and mortality weekly report.

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, BMJ.

Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—Nine States, January–September 2021

S. E. Reese, C. Mcevoy, S. Schrag, 2021, American Journal of Transplantation.

Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022.

S. E. Reese, C. Mcevoy, P. Embí, 2022, The Journal of infectious diseases.

Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods

William F. Fadel, S. E. Reese, C. Mcevoy, 2023, JAMA network open.

High Burden of COVID-19 among Unvaccinated Law Enforcement Officers and Firefighters

Lauren E. W. Olsho, K. Hegmann, A. Fowlkes, 2021, medRxiv.

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2023, MMWR. Morbidity and mortality weekly report.

Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents.

S. E. Reese, M. Stockwell, R. Link-Gelles, 2023, Pediatrics.

Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021–February 2022, VISION Network: a retrospective cohort study

R. Link-Gelles, P. Embí, K. Natarajan, 2023, Lancet regional health. Americas.